gotta hand it to pfizer.
they demolish all competition.
roll up for your 4 th experimental vaccine, when an aussie company has been waiting 12 months for approval and has just got fined
COVAX-19 FAQ
Who is Vaxine?
Vaxine was incorporated in 2002 as an Australian biotechnology company focusing on development of innovative vaccine technologies, with its lead product being its Advax delta inulin adjuvant.
Supported by funding contracts from the National Institutes of Health, Vaxine has developed a broad range of vaccines, all utilizing its Advax adjuvant technology for enhanced immunogenicity and protection. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, COVID-19, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy. Vaxine also has a veterinary division that is commercialising vaccine adjuvants tailored to specific animal health problems.
Vaxine has developed a recombinant protein-based vaccine against COVID-19 which is currently in advanced clinical development and it is hoped this vaccine will achieve emergency use approval in 2022.
You can read more about Vaxine’s projects here.
About the Covax-19 vaccine
How does the Covax-19 vaccine work?
COVAX-19 vaccine is designed to protect against SARS-CoV-2 infection by generation of neutralising antibodies and cellular responses against the virus.
Most recently, a pivotal Phase 3 trial in Iran involving 16,876 participants demonstrated robust protection against the notorious Delta variant.
With these results, in early October 2021 it received market authorisation for emergency use from the Iranian FDA. Already over 2 million doses have been safely distributed by Iranian immunisation centres.
Notably, the Phase 2 trial showed induction of neutralising antibodies against all the major variants of concern indicating very broad cross-protection. In support of this, it provided strong protection against a range of virus variants (Wuhan, Beta, Delta) in animal challenge models, with studies in hamsters, ferrets and monkeys. Notably, it was shown to block SARS-CoV-2 virus shedding from the nose and thereby prevented transmission from challenged to naive animals, a unique finding.
On the safety side, it has been extremely well tolerated with no vaccine-associated serious adverse reactions seen in the clinical trials or in post-market pharmaco-vigilance. Notably, there have been no cases reported of myocarditis/pericarditis, arrythmias or sudden death, or central venous thrombosis.
Are Covax-19 and Novavax the same?
COVAX-19 differs from its USA competitor NOVAVAX in a number of ways. COVAX-19 is an Australian developed vaccine by an Australian physician and scientist, Prof. Nikolai Petrovsky and his Team at Vaxine Pty Ltd. Novavax is a US based company who use the full length protein spike whereas COVAX-19 uses a trimmed down protein. We also use an adjuvant which is like a “turbo-charger” for vaccines which is made from Inulin, a plant fructose.
What is the difference between COVAX-19 and the mRNA vaccines that are currently available in Australia?
Covax-19 is a protein based vaccine. Protein based vaccines have been around for over 50 years and have had extensive longitudinal studies conducted on them over that period of time. We know that a protein based vaccine is well tolerated with few side effects.
mRNA vaccines are gene therapies that have only recently been administered to humans, the mRNA. In this video Rob Malone, the inventor of mRNA explains the mRNA vaccine.
Forum
Pages: 1 
